Eddie Hickman
Stock Analyst at Guggenheim
(3.52)
# 742
Out of 5,182 analysts
21
Total ratings
65%
Success rate
19.78%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Eddie Hickman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TARS Tarsus Pharmaceuticals | Maintains: Buy | $87 → $90 | $70.12 | +28.35% | 10 | Feb 25, 2026 | |
| PMN ProMIS Neurosciences | Maintains: Buy | $125 → $35 | $12.51 | +179.78% | 4 | Feb 6, 2026 | |
| ATAI AtaiBeckley | Initiates: Buy | $11 | $3.79 | +190.24% | 1 | Jan 20, 2026 | |
| OTLK Outlook Therapeutics | Downgrades: Neutral | n/a | $0.22 | - | 4 | Aug 29, 2025 | |
| ZVRA Zevra Therapeutics | Maintains: Buy | $20 → $22 | $9.40 | +134.04% | 1 | Mar 13, 2025 | |
| GHRS GH Research | Initiates: Buy | $32 | $14.57 | +119.63% | 1 | Mar 13, 2025 |
Tarsus Pharmaceuticals
Feb 25, 2026
Maintains: Buy
Price Target: $87 → $90
Current: $70.12
Upside: +28.35%
ProMIS Neurosciences
Feb 6, 2026
Maintains: Buy
Price Target: $125 → $35
Current: $12.51
Upside: +179.78%
AtaiBeckley
Jan 20, 2026
Initiates: Buy
Price Target: $11
Current: $3.79
Upside: +190.24%
Outlook Therapeutics
Aug 29, 2025
Downgrades: Neutral
Price Target: n/a
Current: $0.22
Upside: -
Zevra Therapeutics
Mar 13, 2025
Maintains: Buy
Price Target: $20 → $22
Current: $9.40
Upside: +134.04%
GH Research
Mar 13, 2025
Initiates: Buy
Price Target: $32
Current: $14.57
Upside: +119.63%